Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu; "Sysmex") will present the most recent data on using blood as a method of diagnosing Alzheimer’s disease at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2021), held virtually from March 9 to 14, 2021. Sysmex is conducting this development in collaboration with Eisai Co., Ltd. (HQ: Tokyo, Japan; CEO: Haruo Naito; "Eisai").
In February 2016, Sysmex and Eisai signed a non-exclusive comprehensive agreement aimed at the creation of new diagnostics in the field of dementia. By leveraging each other’s technologies and knowhow, we aim to discover next-generation diagnostic drugs that will enable the early diagnosis, selection of treatment options, and regular monitoring of the effects of treatment for dementia. Sysmex and Eisai are pursuing joint development aimed at creating a simple method of diagnosing Alzheimer’s disease using blood. At AD/PD 2021, Sysmex will announce the most recent data regarding prediction of amyloid positivity by incorporating the APOE4 status into plasma Aβ ratio measurement on the HISCLTM automated immunoassay system.
|Asset in Development, Session Name||Topic/Planned Date and Time (Eastern Standard Time)||Presenter (Affiliation)|
|AD Diagnostics “Amyloid, Tau, and Synapse PET Imaging”||A Fully Automated Plasma Aβ Assay Incorporating APOE4 Status Shows High Performance to Predict Amyloid Positivity Determined by Centiloids of Amyloid PET Session time: March 12 (Fri.) 10:00-12:00 Oral presentation: 11:15-11:30; live Q&A session: 16:30-17:00||Kazuto Yamashita (Sysmex)|
Sysmex is working to create new diagnostic technologies for the prevention and treatment of dementia. We aim to contribute to the advancement of healthcare and improve the quality of life for patients and their families.